Moberg Pharma’s CEO divests shares - remains large long-term shareholder

STOCKHOLM, February 16th 2017. Moberg Pharma AB (OMX: MOB) announces that Peter Wolpert, founder and CEO of Moberg Pharma, has divested 164,601 shares in Moberg Pharma.

Following the divestment, Peter Wolpert holds 435,399 shares, remaining one of the ten largest shareholders in the company. Furthermore, he holds stock options entitling him to subscribe for another 125,000 shares.

"The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company”, says Peter Wolpert, CEO of Moberg Pharma.

The transaction has been reported to Sweden's financial supervisory authority (Finansinspektionen) according to regulations.

This information
The information was submitted for publication, through the agency of the contact person set out above, at 4.00 p.m. (CET) on February 16th 2017. 

For additional information, please contact:
Peter Wolpert, CEO, telephone: +46 70 735 71 35, e-mail: peter.wolpert@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com  
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, DermoPlast®, Domeboro® and Fiber Choice®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis, phase 3 studies ongoing) and BUPI (pain management in oral mucositis, phase 3 preparations ongoing). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).

Tags:

About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The ompany’s portfolio includes the OTC brands Kerasal®, Kerasal Nail®, Balmex®, NewSkin®, Dermoplast®, Domeboro® and Fiber Choice®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada as well as in several markets in EU and Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focus on innovative drug delivery of proven compounds and include two clinical stage assets, MOB-015 (onychomycosis) and BUPI (pain management in oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).For further information, please visit: www.mobergpharma.com.

Contacts

Subscribe

Quotes

The divestment is made for personal financial reasons and I don’t intend to sell additional shares. I have great faith in the prospects for Moberg Pharma and I look forward to continuing to build the company
Peter Wolpert, CEO of Moberg Pharma